Clinical trials: Ticagrelor
Coronary Artery Disease
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
Two strategies have both proven to be effective in reducing bleeding complications while preserving efficacy compared with maintaining long-term DAPT with aspirin and a potent P2Y12 inhibitor: a) DAPT de-escalation (i.e.…
- Trial name
- TAILOR BLEED (NCT05681702)
- Testing
- aspirin plus clopidogrel, prasugrel or ticagrelor
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- University of Florida
Myocardial Infarction, Thrombosis
CES1 Crossover Trial of Clopidogrel and Ticagrelor
The purpose of this investigation is to evaluate when genetic variation in the carboxylesterase 1 (CES1) gene influences antiplatelet therapy response, as assessed by ex vivo platelet aggregometry, in healthy participants treated…
- Conditions
- Myocardial Infarction, Thrombosis, Platelet Dysfunction
- Trial name
- NCT03161678
- Testing
- Clopidogrel, Ticagrelor
- Where
- United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Insomnia
A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy Subjects
Primary Objective : To evaluate the effect of ticagrelor tablets on the pharmacokinetic characteristics of YZJ-1139 in healthy subjects; Secondary Objective: To evaluate the safety of ticagrelor tablets in combination with…
- Trial name
- NCT06671470
- Testing
- YZJ-1139 tablets, Ticagrelor Tablets
- Where
- China
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Coronary Artery Disease, Coronary Artery Bypass Grafting
Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG
This randomized controlled trial aims to evaluate the impact of different durations of Ticagrelor-based dual antiplatelet therapy (DAPT) on saphenous vein graft (SVG) patency in patients undergoing coronary artery bypass grafting…
- Conditions
- Coronary Artery Disease, Coronary Artery Bypass Grafting, Saphenous Vein, Dual Antiplatelet Therapy
- Trial name
- NCT06981390
- Testing
- Ticagrelor + Aspirin for 3 Months (followed by aspirin monotherapy), Ticagrelor + Aspirin for 6 Months (followed by aspirin monotherapy), Ticagrelor + Aspirin for 12 Months (followed by aspirin monotherapy)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Kexiang Liu, MD
Healthy
Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination.
Study conducted to determine and compare the relative bioavailability of two solid oral formulations (reference versus test) of the non-fixed combination of Ticagrelor 90 mg (Brilinta by AstraZeneca S.A.
- Trial name
- NCT07444164
- Testing
- A1: Ticagrelor / Acetylsalicylic acid in fixed dose combination capsule. (Laboratorios Silanes S.A. de C.V.), A2: Ticagrelor (BRILINTA®, AstraZeneca S.A. de C.V.) A3: Acetylsalicylic Acid (ASPIRINA JUNIOR®, Bayer de México S.A. de C.V.)
- Where
- Mexico
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Healthy Volunteer
Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers
This is a non-randomized, open-label, fixed-sequence drug-drug interaction study to evaluate the effects of itraconazole and ticagrelor on the pharmacokinetics of catequentinib hydrochloride (AL3818) in healthy volunteers.
- Trial name
- NCT07438886
- Testing
- AL3818 Capsule, Itraconazole capsule, Ticagrelor Tablets
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Advenchen Laboratories Nanjing Ltd.
Acute Coronary Syndrome
The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin
Heart attacks are usually caused by clots in a coronary artery, depriving the heart muscle of blood. Platelets are the main type of blood cell causing clots to form and physicians typically give a combination of two anti-platelet…
- Trial name
- WILLOW TREE (NCT03869268)
- Testing
- Aspirin, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Healthy
A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects
The primary objective of this study is to assess the pharmacodynamic (PD) effects of clopidogrel, prasugrel, and ticagrelor when administered after a single subcutaneous (s.c.) dose of ACT-246475 in healthy male and female…
- Trial name
- NCT03430661
- Testing
- ACT-246475, Clopidogrel, Prasugrel
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Viatris Innovation GmbH
Ischemic Stroke, Transient Ischemic Attack
Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke
This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy…
- Trial name
- DEDAPT-TICA (NCT06653348)
- Testing
- Ticagrelor 60 + Aspirin, Ticagrelor 90 + aspirin
- Where
- Iran
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mazandaran University of Medical Sciences
Healthy Participants
A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants
The purpose of this study is to measure the effect of ticagrelor on the pharmacokinetics (PK) of rosuvastatin in healthy participants.
- Trial name
- NCT06554821
- Testing
- Rosuvastatin, Ticagrelor
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Acute Coronary Syndrome, Ischemic Stroke
Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects
This study is designed to evaluate the pharmacokinetics, pharmacodynamics and safety in healthy subjects with multiple administration of Tiprogrel.
- Trial name
- NCT06584812
- Testing
- Tiprogrel, Clopidogrel, Ticagrelor
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Tianjin Institute of Pharmaceutical Research Co., Ltd
Healthy
Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers
This is a Phase 1, first-in-human, randomized, double-blind, placebo-controlled, single ascending dose, sequential group study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PB2452 with and…
- Trial name
- NCT03492385
- Testing
- PB2452 Infusion, Ticagrelor Oral Tablet - Pre-Treatment, Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- SFJ Pharmaceuticals, Inc.
Healthy
Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects
This is a Phase 2A, randomized, double-blind, placebo-controlled, single dose, sequential group study to evaluate the safety, tolerability, PK, and PD of PB2452 vs matching placebo with ticagrelor (with or without acetylsalicylic…
- Trial name
- NCT03928353
- Testing
- PB2452 Infusion, Ticagrelor Oral Tablet - Pre-Treatment, Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- SFJ Pharmaceuticals, Inc.
Healthy
Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old
This phase 2B study is a multi-center, randomized, double-blind, placebo-controlled study. The study is designed to evaluate the efficacy of bentracimab (PB2452) in reversing the anti-platelet effects of ticagrelor as part of a…
- Trial name
- NCT04122170
- Testing
- Ticagrelor Oral Tablet - Pre-Treatment, Aspirin (ASA) Oral Tablet - Pre-Treatment, Bentracimab (PB2452) Infusion
- Where
- 15 sites in United States, Canada
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- SFJ Pharmaceuticals, Inc.
Intracranial Aneurysm, Stent Complication
Stent-Assisted Coiling Followed by Ticagrelor Monotherapy Instead of Dual Antiplatelet Therapy in Unruptured Intracranial Aneurysm
The primary goal of the trial is to investigate whether the experimental arms (receiving the P2Y12 inhibitor Ticagrelor) compared with the control arm (taking dual antiplatelet therapy) could reduce bleeding complications in…
- Trial name
- SAC-TIDE (NCT06015477)
- Testing
- Ticagrelor monotherapy, Dual Antiplatelet Therapy
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Healthy Subjects
Ticagrelor Tablets 90 mg Relative to Originator Ticagrelor Tablets 90 mg
The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose.
- Trial name
- TIC-025-23 (NCT06233266)
- Testing
- Ticagrelor-Test product, Ticagrelor-Reference product
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bio-innova Co., Ltd
Healthy
Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose, sequential group study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PB2452 (Bentracimab) with and without…
- Trial name
- NCT05162131
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- SFJ Pharmaceuticals, Inc.
Cardiovascular Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
Part A of this study is a Phase 1, First-in-human (FiH), randomized, single-blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD3366 following single…
- Trial name
- NCT04588727
- Testing
- AZD3366, Ticagrelor, acetylsalicylic acid (ASA)
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Coronary Artery Disease, Healthy Participants
A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants
The purpose of this study is to assess the effectiveness, safety and tolerability of BMS-986141 added on to aspirin or ticagrelor or the combination on thrombus formation in both healthy participants and participants with stable…
- Trial name
- NCT05093790
- Testing
- Ticagrelor, BMS-986141, Aspirin
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Ischemic Stroke, Transient Ischemic Attack
Efficacy of Ticagrelor Plus Aspirin in Mild Non-cardioembolic Ischemic Stroke
This is a randomized, controlled, active comparator arm, outcome assessor blind, parallel group design on 90 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is assess the…
- Trial name
- TACAMINIS (NCT04738097)
- Testing
- Ticagrelor 90mg, Clopidogrel 75 mg
- Where
- 2 sites in Iran
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Mazandaran University of Medical Sciences